Results 21 to 30 of about 16,360 (195)

Benefits of Autoantibody Enrichment in Early Rheumatoid Arthritis: Analysis of Efficacy Outcomes in Four Pooled Abatacept Trials

open access: yesRheumatology and Therapy, 2023
Introduction The efficacy of abatacept is enhanced in anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF)-positive versus -negative patients with rheumatoid arthritis (RA).
Kaleb Michaud   +10 more
doaj   +1 more source

Tocilizumab and Abatacept for the Treatment of Childhood Chronic Uveitis: A Monocentric Comparison Experience

open access: yesFrontiers in Pediatrics, 2022
BackgroundOur study aimed to evaluate the efficacy of Tocilizumab and Abatacept for treating Childhood Chronic non-infectious Uveitis (CCU), resistant to anti-tumor necrosis factor (anti-TNF) treatment.MethodsThis is a monocentric retrospective charts ...
Ilaria Maccora   +9 more
doaj   +1 more source

Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

open access: yesGlobal & Regional Health Technology Assessment, 2021
Purpose: The objective of this economic evaluation was to compare the cost per responder between upadacitinib and abatacept (intravenous [iv] or subcutaneous [sc]) in patients with moderate-to-severe Rheumatoid Arthritis (RA) in Italy.
Roberto Caporali   +3 more
doaj   +1 more source

Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis

open access: yesArthritis Research & Therapy, 2021
Objectives The aim of this study was to compare the clinical effectiveness of tofacitinib and abatacept and clarify the impact of the HLA-DRB1 shared epitope (SE) on responses to these treatments in patients with rheumatoid arthritis (RA).
Wataru Hirose   +10 more
doaj   +1 more source

Immunomodulatory mechanisms of abatacept: A therapeutic strategy for COVID-19

open access: yesFrontiers in Medicine, 2022
Coronavirus disease 2019 (COVID-19) caused by coronavirus-2 (SARS-CoV-2) infection has rapidly spread throughout the world and become a major threat to human beings. Cytokine storm is a major cause of death in severe patients.
Dinglong Yang   +6 more
doaj   +1 more source

HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA

open access: yesArthritis Research & Therapy, 2021
Background Certain risk alleles associated with autoantibody-positive rheumatoid arthritis (RA) have been linked to poorer prognoses. In patients with autoantibody-positive RA, abatacept shows differential efficacy to tumor necrosis factor inhibitors ...
William Rigby   +7 more
doaj   +1 more source

Abatacept therapy and safety management.

open access: yes, 2009
International audienceObjectives: To elaborate a how-to-use abatacept material intended to help physicians in the management of patients with inflammatory diseases treated with this drug in routine practice.
Hachulla, Eric   +29 more
core   +3 more sources

T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis

open access: yesArthritis Research & Therapy, 2018
Background We aimed to investigate the efficacy of abatacept in preclinical mouse models of digestive involvement, pulmonary fibrosis, and related pulmonary hypertension (PH), mimicking internal organ involvement in systemic sclerosis (SSc).
Gonçalo Boleto   +10 more
doaj   +1 more source

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis. [PDF]

open access: yes, 2020
In ASTRAEA (NCT01860976), abatacept significantly increased American College of Rheumatology criteria 20% (ACR20) responses at Week 24 versus placebo in patients with psoriatic arthritis (PsA).
McInnes, Iain B   +6 more
core   +3 more sources

Subcutaneous abatacept versus intravenous abatacept a phase IIIb noninferiority study in patients with an inadequate response to methotrexate

open access: yes, 2011
Objective To compare the efficacy and safety of subcutaneous (SC) and intravenous (IV) abatacept. Methods In this phase IIIb double-blind, double-dummy, 6-month study, patients with rheumatoid arthritis (RA) and inadequate responses to methotrexate were ...
Mysler, E   +58 more
core   +2 more sources

Home - About - Disclaimer - Privacy